

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Andreas Lindenschmidt	09/18/2007
Holger Wagner	09/19/2007
Jochen Beninga	09/20/2007
Sven Grueneberg	12/14/2007
Klaus-Ulrich Weithmann	09/20/2007
RECEIVING PARTY DATA	
Name:	Sanofi-Aventis Deutschland GmbH
Street Address:	Industriepark Hoechst
City:	65929 Frankfurt am Main
State/Country:	GERMANY
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11763618
CORRESPONDENCE DATA	
Fax Number:	(908)231-2626
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	908-231-5674
Email:	maribel.mendez@sanofi-aventis.com
Correspondent Name:	Raymond S. Parker
Address Line 1:	1041 Route 202-206
Address Line 4:	Bridgewater, NEW JERSEY 08807
ATTORNEY DOCKET NUMBER:	DEAV2004/0081 US CNT
NAME OF SUBMITTER:	Maribel Mendez

CH \$40.00 11763618

Total Attachments: 3
 source=DEAV2004-0081 US CNT - Executed Assignment#page1.tif

500435380

PATENT
REEL: 020341 FRAME: 0059

source=DEAV2004-0081 US CNT - Executed Assignment#page2.tif
source=DEAV2004-0081 US CNT - Executed Assignment#page3.tif

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Andreas Lindenschmidt, 65812 Bad Soden, Germany
- 2) Dr. Holger Wagner, 88400 Biberach/Mettenberg, Germany
- 3) Dr. Jochen Beringa, 55129 Mainz, Germany
- 4) Dr. Sven Grueneberg, 65779 Kelkheim, Germany
- 5) Dr. Klaus-Ulrich Weithmann, 65719 Hofheim, Germany

The inventors are citizens of: 1) - 5) Germany

hereby sell, assign, and transfer unto **Sanofi-Aventis Deutschland GmbH**, a corporation organized under the laws of **Germany**, located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of the United States, executed concurrently herewith

Ser.-No.: 11763618

filed: June 15, 2007

entitled: **Novel cyclic ureas used as inhibitors of metalloproteases**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

Inventor(s):

1st: Andreas Lindenschmidt Date: 18.09.2007

2nd: _____ Date: _____

3rd: Jochen Beringa Date: 20.09.2007

4th: _____ Date: _____

5th: Klaus-Ulrich Weithmann Date: 20.09.2007

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Andreas Lindenschmidt, 65812 Bad Soden, Germany
- 2) Dr. Holger Wagner, 88400 Biberach/Mettenberg, Germany
- 3) Dr. Jochen Beninga, 55129 Mainz, Germany
- 4) Dr. Sven Grueneberg, 65779 Kelkheim, Germany
- 5) Dr. Klaus-Ulrich Weithmann, 65719 Hofheim, Germany

The inventors are citizens of: 1) - 5) Germany

hereby sell, assign, and transfer unto **Sanofi-Aventis Deutschland GmbH**, a corporation organized under the laws of **Germany**, located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of the United States , executed concurrently herewith

Ser.-No.: **11/763618**

filed: **June 15, 2007**

entitled: **Novel cyclic ureas used as inhibitors of metalloproteases**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said application for Letters Patent, and in and to all divisional or continuation applications that may be filed for United States Letters Patent for any of said inventions, and in and to all patents that may be granted on the foregoing applications, and I/we hereby agree, whenever requested, to communicate to said assignee, its successors and assigns, any facts known to me/us respecting said inventions, to testify in any legal proceeding, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in the United States.

inventor(s):

1st: _____ Date: _____

2nd: Holger Wagner Date: 19.9.2007

3rd: _____ Date: _____

4th: _____ Date: _____

5th: _____ Date: _____

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Andreas Lindenschmidt, 65812 Bad Soden, Germany
- 2) Dr. Holger Wagner, 88400 Biberach/Mettenberg, Germany
- 3) Dr. Jochen Beninga, 55129 Mainz, Germany
- 4) Dr. Sven Grueneberg, 65779 Kelkheim, Germany
- 5) Dr. Klaus-Ulrich Weithmann, 65719 Hofheim, Germany

The inventors are citizens of: 1) - 5) Germany

hereby sell, assign, and transfer unto **Sanofi-Aventis Deutschland GmbH**,
a corporation organized under the laws of **Germany**,
located at **D-65929 Frankfurt am Main, Germany**,

the entire right, title and interest in and to my/our application for Letters Patent of
the United States , executed concurrently herewith

Ser.-No.: **11/763618**

filed: **June 15, 2007**

entitled: **Novel cyclic ureas used as inhibitors of metalloproteases**


and my/our entire right, title, and interest in and to all my/our inventions disclosed in said
application for Letters Patent, and in and to all divisional or continuation applications that
may be filed for United States Letters Patent for any of said inventions, and in and to all
patents that may be granted on the foregoing applications, and I/we hereby agree, whenever
requested, to communicate to said assignee, its successors and assigns, any facts known to
me/us respecting said inventions, to testify in any legal proceeding, and to execute all
applications or papers necessary to obtain and maintain proper patent protection on said
inventions in the United States.

Inventor(s):

1st: _____ Date: _____

2nd: _____ Date: _____

3rd: _____ Date: _____

4th:  _____ Date: 14.12.2007

5th: _____ Date: _____

PATENT